Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | PNMT | P11086 | 6/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | CD44 | P16070 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2996134 | 0.86 | PNMT (0.36) | APEX1PNMTMAPTCYP2C19ALDH1A1 | |
| SCHEMBL6421619 | 0.84 | PNMT (0.44) | APEX1PNMT | |
| SCHEMBL17377150 | 0.78 | APEX1 (0.43) | APEX1PNMTMEN1GABRA1CYP2C19 | |
| SCHEMBL18379152 | 0.76 | CD44 (0.43) | APEX1PNMTADORA1MEN1GABRA1 | |
| SCHEMBL18368345 | 0.76 | APEX1 (0.40) | APEX1PNMTMEN1GABRA1CYP2C19 | |
| SCHEMBL21263695 | 0.76 | APEX1 (0.40) | APEX1PNMTADORA1MEN1GABRA1 | |
| SCHEMBL15908241 | 0.76 | APEX1 (0.40) | APEX1PNMTADORA1MEN1GABRA1 | |
| SCHEMBL15848407 | 0.73 | PNMT (0.41) | APEX1PNMTMEN1GABRA1CYP2C19 | |
| SCHEMBL13021599 | 0.72 | HPGD (0.44) | MAPTCYP2C19ALDH1A1HPGDNR2E3 | |
| SCHEMBL3715448 | 0.71 | PTPRC (0.42) | APEX1PNMTADORA1MAPTGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3896064-A1 | 4,6-DIAMINO-QUINOLINE-3-CARBONITRILE DERIVATIVES AS CANCER OSAKA THYROID (COT) MODULATORS FOR TREATING CROHN'S DISEASE AND ULCERATIVE COLITIS | Gilead Sciences, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| EP-3456717-B1 | 4,6-DIAMINO-QUINOLINE-3-CARBONITRILE DERIVATIVE AS CANCER OSAKA THYROID (COT) MODULATOR FOR TREATING INFLAMMATORY DISEASE | GILEAD SCIENCES INC (US) | 2021-03-17 | — | — | EP | disclosed |
| WO-2020252151-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| EP-3617192-A1 | VIRAL REPLICATION INHIBITORS | Katholieke Universiteit Leuven K.U. Leuven R&D (BE) | 2020-03-04 | — | — | EP | disclosed |
| EP-2760831-B1 | VIRAL REPLICATION INHIBITORS | UNIV LEUVEN KATH (BE) | 2019-08-07 | — | — | EP | disclosed |
| EP-3456717-A1 | TABLETS CONTAINING 4,6-DIAMINO-QUINOLINE-3-CARBONITRILE DERIVATIVES AS CANCER OSAKA THYROID (COT) MODULATORS FOR TREATING CANCER | GILEAD SCIENCES, INC. (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170152240-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-06-01 | — | — | US | disclosed |
| EP-3160466-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20170008905-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
| WO-2015200677-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015200677-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-30 | — | — | WO | disclosed |
| US-20140213586-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213586-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | APEX1 3008/4885PNMT 1286/4885ADORA1 2992/4885 |
| US-20170152240-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | APEX1 2318/4885PNMT 476/4885ADORA1 2872/4885 |
| US-20170008905-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | APEX1 2318/4885PNMT 476/4885ADORA1 2872/4885 |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | APEX1 1474/4885PNMT 523/4885ADORA1 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.